NCT02576626View on ClinicalTrials.gov

Single Dose Ultibro Breezhaler by Sd-DPI Versus Ipratropium/Salbutamol by Nebulizer in COPD

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

September 29, 2017

Study Completion Date

September 29, 2017

Conditions
COPD
Interventions
DRUG

indacaterol/glycopyrronium 110/50 Breezhaler®

DEVICE

Placebo by Breezhaler®

DRUG

ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation

DEVICE

Placebo by nebulisation

Trial Locations (1)

9700RB

UMCG, Groningen

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

collaborator

University Medical Center Groningen

OTHER

lead

Wouter H. van Geffen

OTHER